Patients with relapsed or refractory diffuse large B-cell lymphoma who could not receive a stem cell transplant lived a median of 25.5 months on a bispecific antibody combination, compared with 12.5 months on the standard comparison regimen, according to three-year follow-up from a phase 3 trial.
The results, published in Blood Advances, come from the STARGLO trial, which randomized 274 patients 2 to 1 to glofitamab plus gemcitabine and oxaliplatin or to rituximab plus the same chemotherapy backbone. Median follow-up reached 35.1 months. Median progression-free survival was 14.4 months versus 3.3 months, and the complete response rate was 58.5% versus 25.3%.
The durability is the news. A survival advantage at one year can reflect a delay rather than a change in trajectory. Holding at three years is a different signal, and it matters most for a group of patients who have historically had almost nothing to offer them.
The Trial Enrolled the Patients Who Usually Run Out of Options
Diffuse large B-cell lymphoma is the most common aggressive lymphoma. Most patients respond to first-line chemoimmunotherapy, but roughly a third relapse or never fully respond, and outcomes after that point drop sharply.
The conventional next step is high-dose chemotherapy with an autologous stem cell transplant or CAR T-cell therapy. Both require a patient robust enough to tolerate them. Many are not. Older, frailer patients, and patients without practical access to a CAR T center fall outside both options, and the regimens available to them rarely produce complete remission.
Glofitamab belongs to a class called bispecific antibodies. One arm binds CD20 on the surface of the malignant B cell. The other binds CD3 on a T cell. The molecule physically brings the two together, redirecting the patient's own immune cells to kill the lymphoma. It is conceptually similar to CAR T-cell therapy but does not require harvesting and engineering a patient's cells, which is why it can be given as an off-the-shelf product on a fixed schedule rather than as a manufactured one-time infusion.
The fixed duration is a meaningful practical feature. Treatment consists of eight cycles of the combination, followed by four additional cycles of glofitamab alone, and then stops, rather than continuing indefinitely until progression. Benefit was more pronounced in the second-line setting, where the three-year overall survival rate was 54.6 percent compared with 33.2 percent in third-line or later use, according to the company's follow-up announcement.
Cytokine Release Syndrome Is the Trade Off to Understand
The efficacy figures should not be read without the safety ones, and the study reports them plainly.
Serious adverse events and grade 3 or higher adverse events were more common with the glofitamab combination than with the comparator. As noted in a Medscape summary of the three-year data, patients on the glofitamab arm received substantially more treatment overall because they stayed on therapy longer, which inflates cumulative exposure and therefore event counts. That does not erase the difference, but it explains part of it. Grade 3 to 5 infections occurred in 19.8% of the glofitamab group versus 12.5% of the comparator group.
The characteristic toxicity of this drug class is cytokine release syndrome, an inflammatory reaction that occurs when large numbers of T cells activate at once. Symptoms range from fever and low blood pressure to organ dysfunction. In STARGLO, cytokine release syndrome of any grade occurred in about 45 percent of patients but was predominantly low grade, with grade 3 events in roughly 2 percent. In the earlier phase 2 study of glofitamab as a single agent, published in the New England Journal of Medicine, the rate was higher. The regimen includes pretreatment with obinutuzumab and a step-up dosing schedule specifically to reduce that risk, which is why early cycles typically involve close monitoring and often a night in the hospital.
Neurologic events, infections, and low blood counts are also part of the profile. Patients considering this treatment should ask directly about the monitoring plan for the first cycles, whether hospitalization is required for step-up dosing, and what symptoms should trigger an immediate call.
The trial has limits worth stating. It was open-label, meaning patients and investigators knew the assignment. The comparator, rituximab plus gemcitabine and oxaliplatin, is a reasonable standard for transplant-ineligible patients but was not compared against newer cellular or bispecific therapies. And the enrolled population was selected, which limits the extent to which the results generalize to other patients with relapsed or refractory disease.
US Access Is Narrower Than the Trial Results Suggest
Glofitamab carries FDA accelerated approval as a single agent for adults with relapsed or refractory diffuse large B-cell lymphoma after at least two prior lines of therapy. The combination tested in STARGLO, for use after one prior line in transplant-ineligible patients, is a separate matter, and the US regulatory history is the part patients most need to understand.
The FDA accepted a supplemental application for the combination, but in May 2025, its Oncologic Drugs Advisory Committee voted 8 to 1 against the applicability of the trial population and results to US patients, noting that only a small number of participants were enrolled in the United States. In July 2025, the agency issued a complete response letter, concluding that the data did not provide sufficient evidence to support the proposed second-line indication in the US population. The accelerated approval for third-line or later use remains in place.
The picture abroad is different. The European Commission approved the combination for transplant-ineligible patients, and it is authorized in a substantial number of other countries. In the United States, access in the earlier setting depends on participation in clinical trials or off-label use, which insurers may not cover.
Patients and families in this situation have concrete questions. Whether a second opinion at a center that runs lymphoma trials is feasible. Whether CAR T-cell therapy has genuinely been ruled out or simply not offered. What the monitoring requirements would be. And whether a clinical trial is open locally, since participation in a trial often provides access to regimens before approval.
Financial navigation matters here. Academic cancer centers generally have financial counselors, manufacturers run patient assistance programs, and organizations such as the Leukemia & Lymphoma Society provide co-pay assistance for blood cancers.
The company has said that discussions with the FDA are ongoing regarding a different trial to serve as the confirmatory study for full approval. MedicalDaily will report the outcome and any changes in the treatment landscape for transplant-ineligible patients.
Key Questions Answered
What is diffuse large B-cell lymphoma? The most common aggressive lymphoma. Most patients respond to initial chemoimmunotherapy, but roughly a third relapse or do not fully respond, and outcomes worsen substantially after that.
What did the three-year data show? Median overall survival of 25.5 months with glofitamab plus gemcitabine and oxaliplatin versus 12.5 months with rituximab plus the same chemotherapy, in 274 transplant-ineligible patients, at a median follow-up of 35.1 months.
What is a bispecific antibody? A molecule with two binding arms that physically connects a cancer cell to a T cell, redirecting the immune system to attack the tumor. It is given off the shelf rather than manufactured from a patient's own cells.
How is it different from CAR T-cell therapy? CAR T requires collecting and engineering a patient's own T cells, a process many patients cannot access or tolerate. Bispecific antibodies are administered as scheduled infusions without a manufacturing step.
What are the main side effects? Cytokine release syndrome is the characteristic risk, occurring in about 45 percent of patients in this trial and mostly low-grade. Neurologic events, infections, and low blood counts also occur, and serious events were more common with the glofitamab regimen.
Is this combination available in the United States? Not in the earlier transplant-ineligible setting. The FDA issued a complete response letter for that indication. Glofitamab remains approved as a single agent after at least two prior lines.
Is it available anywhere else? Yes. The combination was approved in the European Union for transplant-ineligible patients and is authorized in several other countries.
